Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update (Q36066038)

12 August 2017

1 reference

title

Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update (English)

1 reference

12 August 2017

1 reference

1

Len Neckers

1 reference

12 August 2017

Katharine Neckers

2

1 reference

PubMed ID

15757409

12 August 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

Expert Opinion on Emerging Drugs

12 August 2017

1 reference

12 August 2017

10

1 reference

12 August 2017

1

1 reference

12 August 2017

137-149

1 reference

The onset and extent of genomic instability in sporadic colorectal tumor progression

12 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Modelling the molecular circuitry of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Hsp90: the vulnerable chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

The Hsp90 chaperone complex as a novel target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Heat shock protein 90 as a molecular target for cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Hsp90 as a capacitor for morphological evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Hsp90 as a capacitor of phenotypic variation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

A Nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

The C-terminal half of heat shock protein 90 represents a second site for pharmacologic intervention in chaperone function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Hsp70 and Hsp90--a relay team for protein folding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Structure and functional relationships of Hsp90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Regulation of Hsp90 ATPase activity by the co-chaperone Cdc37p/p50cdc37.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

The Hsp90 complex--a super-chaperone machine as a novel drug target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Maturation of the tyrosine kinase c-src as a kinase and as a substrate depends on the molecular chaperone Hsp90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Effect of geldanamycin on androgen receptor function and stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Hypoxia--a key regulatory factor in tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Aggresome formation in liver cells in response to different toxic mechanisms: role of the ubiquitin-proteasome pathway and the frameshift mutant of ubiquitin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Development of Purine-Scaffold Small Molecule Inhibitors of Hsp90

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Recombinant antibodies: a natural partner in combinatorial antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

HSP90 interacts with and regulates the activity of heat shock factor 1 in Xenopus oocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Geldanamycin provides posttreatment protection against glutamate-induced oxidative toxicity in a mouse hippocampal cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Geldanamycin induces heat shock proteins in brain and protects against focal cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Possible role for serine/threonine phosphorylation in the regulation of the heteroprotein complex between the hsp90 stress protein and the pp60v-src tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Hsp90 phosphorylation is linked to its chaperoning function. Assembly of the reovirus cell attachment protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Out of air is not out of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

Cancer robustness: Tumour tactics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.137

10.1517/14728214.10.1.137

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15757409